BOCA RATON, Fla. — First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD) such as ulcerative...
Latest News
VIENNA, Austria – Rectal cancer is a type of bowel cancer that develops in the last several centimetres of the large intestine, just before the anus. It’s one of the most common cancers in Europe, with over 125,000 people diagnosed annually. Treatment traditionally involves surgery to remove the tumour –...
The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study. Participating clinical sites include, in alphabetical order: * Hospital Clínic of Barcelona, Barcelona: Principal Investigator, Dr. Enric Carreras, MD * Hospital Clínico...
Trent Hills – How many five-year-olds can say they’ve thrown the ceremonial first pitch at a Blue Jay game the night the team’s ace pitcher Roy Halladay is honoured as Sportsperson of the Year, or shared the stage with international pop star John Mayer at a concert in Toronto? Isaac...
TORONTO – As his favourite team and hockey idol played Game 7 on Monday night, five-year-old Deccan Gill was watching and maybe even picking up a thing or two to add to his own repertoire. Deccan, known has “Super Deccan” to his more than 3,000 Instagram followers, routinely posts videos of...
LEUVEN, Belgium, STRASBOURG, France, and PHILADELPHIA — Flamingo Therapeutics (“Flamingo”) today announced the appointment of Andrew E. Denker, MD, PhD., as Chief Medical Officer. Dr. Denker is a physician-scientist with over two decades of biotech and pharmaceutical industry experience in clinical development across multiple modalities and therapeutic areas, including oncology...
LEUVEN, Belgium, STRASBOURG, France and PHILADELPHIA — Flamingo Therapeutics today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy. ...
CAMBRIDGE, Mass. — Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, announced the presentation of data regarding the Phase 1 clinical trial design of FX-909, a highly potent and selective inhibitor of PPARG. “FlareTx has built a robust body...
FORT MYERS, Fla. — A best practices program developed at Florida Cancer Specialists & Research Institute (FCS) has been shown to improve outcomes for adult patients prescribed selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM). Results obtained from a one-year retrospective observational study using data collected by FCS’ Real-World...
Fuzhou, China – Flow immunophenotyping can help diagnose primary myelofibrosis (MF) and differentiate between essential thrombocythemia (ET) and polycythemia vera (PV), according to a new study published in the journal Clinical Cytometry. It is difficult to differentiate between the different types of myeloproliferative neoplasms (MPNs), such as ET, PV, and...